Nanotechnology based assays for validating protein biomarkers Free sex w chat private no membership
Clin Cancer Res 17: 3181-3192, 2011.• Speranza S, Gutierrez M, Kummar S, Strong J, Parker R, Collins J, Yu Y, Cao L, Murgo A, Doroshow J, Chen A.
Phase I Study of the Synthetic Triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in Advanced Solid Tumors.
Further, there is a requirement for a convergence of research, regulatory and drug developer thinking – an effort that will not be accomplished by individual scientists or research institutions.
Research collaborations are needed to foster development of these new endpoints and other biomarkers and, in the United States (US), include ongoing efforts among the Food and Drug Administration (FDA), National Cancer Institute (NCI), academia, and industry.
Although several new oncology drugs have reached the market, more than 80% of drugs for all indications entering clinical development do not get marketing approval, with many failing late in development often in Phase III trials, because of unexpected safety issues or difficulty determining efficacy, including confounded outcomes.
These factors contribute to the high costs of oncology drug development and clearly show the need for faster, more cost-effective strategies for evaluating oncology drugs and better definition of patients who will benefit from treatment.
Cancer 186-95, 2010.• Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Pineda M, Azorsa DO, Yang F, Helman LJ, Meltzer PS.
Eur J Cancer 47: 997-1005, 2011.• Giaccone G, Rajan A, Berman A, Kelly R, Szabo E, Lopez-Chavez A, Trepel J, Lee MJ, Cao L, Espinoza-Delgado I, Spittler J, Loehrer PJ.
Belinostat Phase II Study in Patients with Recurrent or Refractory Advanced Thymic Epithelial Tumors.
Cancer Res 37-48, 2010.• Mayeenuddin LH, Yu Y, Kang Z, Helman LJ, Cao L.
Insulin-like Growth Factor 1 Receptor Antibody Induces Rhabdomyosarcoma Cell Death via a Process Involving AKT and Bcl-x L.